000 | 01973 a2200505 4500 | ||
---|---|---|---|
005 | 20250518073951.0 | ||
264 | 0 | _c20200828 | |
008 | 202008s 0 0 eng d | ||
022 | _a1527-7755 | ||
024 | 7 |
_a10.1200/JCO.19.00816 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aPillai, Rathi N | |
245 | 0 | 0 |
_aRandomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2). _h[electronic resource] |
260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _c02 2020 |
||
300 |
_a613-622 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAged, 80 and over |
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
650 | 0 | 4 |
_aDocetaxel _xtherapeutic use |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aHSP90 Heat-Shock Proteins _xantagonists & inhibitors |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aProgression-Free Survival |
650 | 0 | 4 |
_aSalvage Therapy _xmethods |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aTriazoles _xtherapeutic use |
700 | 1 | _aFennell, Dean A | |
700 | 1 | _aKovcin, Vladimir | |
700 | 1 | _aCiuleanu, Tudor-Eliade | |
700 | 1 | _aRamlau, Rodryg | |
700 | 1 | _aKowalski, Dariusz | |
700 | 1 | _aSchenker, Michael | |
700 | 1 | _aYalcin, Ilker | |
700 | 1 | _aTeofilovici, Florentina | |
700 | 1 | _aVukovic, Vojo M | |
700 | 1 | _aRamalingam, Suresh S | |
773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 38 _gno. 6 _gp. 613-622 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.19.00816 _zAvailable from publisher's website |
999 |
_c30413519 _d30413519 |